reading formulary threads from 2024 and half of it aged badly
denial. That is the whole post, but I will justify it. Everything else people worry about in c/dosinglogs is downstream of it. Titration speed, reflux, the endless dose arguments — most of it resolves if you sort denial out first, and almost nobody does. I say this having got it wrong for 8 months. My ApoB was the…
Strongly agree. Step therapy is predictable if you have the criteria.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
Strongly agree.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
external review is the appeal after insurance says no
resubmission after denial requires new documentation
Sceptical. If this were true we would see it reflected in the data and we do not.
Copay was copay for the copay then another 13% of the total. Read the actual plan document.